Tempest Therapeutics, Inc. (TPST)
0.511
-0.01
(-2.16%)
USD |
NASDAQ |
Oct 23, 16:00
0.5183
+0.01
(+1.43%)
After-Hours: 20:00
Tempest Therapeutics Net Income (Quarterly) : -5.244M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.244M |
| March 31, 2026 | -27.70M |
| December 31, 2025 | -4.021M |
| September 30, 2025 | -3.511M |
| June 30, 2025 | -7.87M |
| March 31, 2025 | -10.86M |
| December 31, 2024 | -13.81M |
| September 30, 2024 | -10.56M |
| June 30, 2024 | -9.57M |
| March 31, 2024 | -7.904M |
| December 31, 2023 | -7.488M |
| September 30, 2023 | -6.786M |
| June 30, 2023 | -7.581M |
| March 31, 2023 | -7.636M |
| December 31, 2022 | -9.103M |
| September 30, 2022 | -8.947M |
| June 30, 2022 | -9.168M |
| March 31, 2022 | -8.491M |
| December 31, 2021 | -7.779M |
| September 30, 2021 | -8.11M |
| June 30, 2021 | -7.058M |
| March 31, 2021 | -5.355M |
| December 31, 2020 | -4.32M |
| September 30, 2020 | -5.431M |
| June 30, 2020 | -5.229M |
| Date | Value |
|---|---|
| March 31, 2020 | -12.00M |
| December 31, 2019 | -12.70M |
| September 30, 2019 | -11.63M |
| June 30, 2019 | -9.871M |
| March 31, 2019 | -10.37M |
| September 30, 2018 | -7.891M |
| June 30, 2018 | -5.042M |
| March 31, 2018 | -4.386M |
| December 31, 2017 | -8.528M |
| September 30, 2017 | -9.367M |
| June 30, 2017 | -18.19M |
| March 31, 2017 | -14.90M |
| December 31, 2016 | -22.64M |
| September 30, 2016 | -19.29M |
| June 30, 2016 | -18.57M |
| March 31, 2016 | -21.76M |
| December 31, 2015 | -20.60M |
| September 30, 2015 | -17.92M |
| June 30, 2015 | -17.49M |
| March 31, 2015 | -17.21M |
| December 31, 2014 | -18.89M |
| September 30, 2014 | -12.92M |
| June 30, 2014 | -9.893M |
| March 31, 2014 | -7.814M |
| December 31, 2013 | -11.00M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 5.244M |
| EPS Diluted (Quarterly) | -0.3445 |
| Enterprise Value | 14.95M |
| Earnings Yield | -877.7% |
| Normalized Earnings Yield | -599.73 |